Physician profile
Gulshan Parasher
NPI 1598786733
$65,809.94
in general payments reported to CMS, 2019-2025
24 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $9,239 · 2021: $1,900 · 2022: $7,564 · 2023: $1,363 · 2024: $10K · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,200 · Food and Beverage: $2,992 · Travel and Lodging: $1,980 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,200.00 |
| Food and Beverage | $2,992.26 |
| Travel and Lodging | $1,980.29 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34,859.20 | 2019-2025 | |
| Boston Scientific Corporation | $12,960.47 | 2019-2025 | Exalt Model D, Spyglass |
| Wilson Cook Medical Incorporated | $12,402.58 | 2019-2024 | Hemospray |
| Cook Medical LLC | $2,198.68 | 2019-2025 | Hemospray, Fusion, Echotip |
| Medtronic, INC. | $923.63 | 2024-2025 | Gi Genius |
| Ovesco Endoscopy USA, INC. | $472.48 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $408.06 | 2019-2025 | Entyvio, Eohilia |
| Ambu INC. | $365.30 | 2020-2021 | |
| Endogastric Solutions, INC | $234.35 | 2021-2023 | Esophyx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.36 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $183.91 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $147.04 | 2024 | Iqirvo |
| Exelixis INC. | $68.51 | 2019-2025 | Cabometyx |
| Mallinckrodt Hospital Products INC. | $68.20 | 2024-2025 | Terlivaz |
| Ucb, INC. | $49.19 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $47.98 | 2024 | Ibsrela |
| Olympus America INC. | $34.85 | 2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Erbe USA INC | $33.10 | 2023 | Erbe Vio3 Apc3 Erbejet |
| Array Biopharma INC | $29.43 | 2025 | Tukysa, Braftovi |
| Intercept Pharmaceuticals, INC. | $26.33 | 2019 | |
| Phathom Pharmaceuticals, INC. | $20.29 | 2024 | Voquezna |
| Celgene Corporation | $19.78 | 2023 | Zeposia |
| Merit Medical Systems INC | $15.42 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.80 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gulshan Parasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.